WO2001030398A3 - Ligand chelated paramagnetic mri contrast agents - Google Patents

Ligand chelated paramagnetic mri contrast agents Download PDF

Info

Publication number
WO2001030398A3
WO2001030398A3 PCT/US2000/041385 US0041385W WO0130398A3 WO 2001030398 A3 WO2001030398 A3 WO 2001030398A3 US 0041385 W US0041385 W US 0041385W WO 0130398 A3 WO0130398 A3 WO 0130398A3
Authority
WO
WIPO (PCT)
Prior art keywords
contrast agents
mri contrast
mri
imaging
chelated paramagnetic
Prior art date
Application number
PCT/US2000/041385
Other languages
French (fr)
Other versions
WO2001030398A2 (en
Inventor
Craig F Ferris
Robert E Carraway
Jean A King
Lech Dudycz
Original Assignee
Insight Neuroimaging Systems L
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Insight Neuroimaging Systems L filed Critical Insight Neuroimaging Systems L
Priority to AU21191/01A priority Critical patent/AU2119101A/en
Publication of WO2001030398A2 publication Critical patent/WO2001030398A2/en
Publication of WO2001030398A3 publication Critical patent/WO2001030398A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/085—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier conjugated systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/14—Peptides, e.g. proteins

Abstract

Compounds and methods for imaging by MRI tissues having predetermined cellular receptors are described. The imaging agents comprise a receptor-binding ligand covalently bound to a paramagnetic chelate, optionally in combination with compound for enhancing cellular uptake of said agent. Improved MRI is achieved by acquiring MRI signals after period of time sufficient to achieve receptor mediated cellular concentration of the imaging agent.
PCT/US2000/041385 1999-10-22 2000-10-20 Ligand chelated paramagnetic mri contrast agents WO2001030398A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU21191/01A AU2119101A (en) 1999-10-22 2000-10-20 Ligand chelated paramagnetic mri contrast agents

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US16099099P 1999-10-22 1999-10-22
US16093399P 1999-10-22 1999-10-22
US60/160,990 1999-10-22
US60/160,933 1999-10-22

Publications (2)

Publication Number Publication Date
WO2001030398A2 WO2001030398A2 (en) 2001-05-03
WO2001030398A3 true WO2001030398A3 (en) 2002-03-21

Family

ID=26857346

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/041385 WO2001030398A2 (en) 1999-10-22 2000-10-20 Ligand chelated paramagnetic mri contrast agents

Country Status (2)

Country Link
AU (1) AU2119101A (en)
WO (1) WO2001030398A2 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI284539B (en) 2001-07-30 2007-08-01 Epix Pharm Inc A method for making a magnetic resonance (MR) imaging agent, a MR imaging contrast agent, a method for altering stability of a peptide and a modified peptide
US6987270B2 (en) 2003-05-07 2006-01-17 General Electric Company Method to account for event losses due to positron range in positron emission tomography and assay of positron-emitting isotopes
JP5377965B2 (en) 2005-09-09 2013-12-25 ジョージア ステート ユニバーシティ リサーチ ファウンデーション、インコーポレイテッド Targeted contrast agents and methods for targeting contrast agents
CA2621763C (en) * 2005-09-09 2021-04-06 Georgia State University Research Foundation, Inc. Targeted contrast agents and methods for targeting contrast agents
WO2008019123A2 (en) 2006-08-04 2008-02-14 Georgia State University Research Foundation, Inc. Enzyme sensors, methods for preparing and using such sensors, and methods of detecting protease activity
US8420327B2 (en) 2006-12-14 2013-04-16 Georgia State University Research Foundation Analyte sensors, methods for preparing and using such sensors, and methods of detecting analyte activity
WO2009146099A2 (en) 2008-04-02 2009-12-03 Georgia State University Research Foundation, Inc. Contrast agents, methods for preparing contrast agents, and methods of imaging
WO2011006985A1 (en) * 2009-07-16 2011-01-20 INSERM (Institut National de la Santé et de la Recherche Médicale) Neurotensin analogues for radioisotope targeting to neurotensin receptor-positive tumors
US9956304B2 (en) 2012-06-05 2018-05-01 Georgia State University Research Foundation, Inc. Contrast agents, methods for preparing contrast agents, and methods of imaging
WO2023279073A1 (en) * 2021-07-01 2023-01-05 Amicus Therapeutics, Inc. Neurotensin variants and tagged proteins comprising neurotensin or sortilin propeptide

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995022341A1 (en) * 1994-02-18 1995-08-24 Mallinckrodt Medical, Inc. Labelled peptide compounds
WO1998033531A1 (en) * 1997-02-03 1998-08-06 Mallinckrodt Medical, Inc. Method for the detection and localization of malignant human tumours
WO2000078796A2 (en) * 1999-06-24 2000-12-28 Mallinckrodt Inc. Labeled neurotensin derivatives with improved resistance to enzymatic degradation

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995022341A1 (en) * 1994-02-18 1995-08-24 Mallinckrodt Medical, Inc. Labelled peptide compounds
WO1998033531A1 (en) * 1997-02-03 1998-08-06 Mallinckrodt Medical, Inc. Method for the detection and localization of malignant human tumours
AU728712B2 (en) * 1997-02-03 2001-01-18 Mallinckrodt, Inc. Method for the detection and localization of malignant human tumours
WO2000078796A2 (en) * 1999-06-24 2000-12-28 Mallinckrodt Inc. Labeled neurotensin derivatives with improved resistance to enzymatic degradation

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
TENNEY, J. (1) ET AL: "NMR imaging of neurotensin receptors in the brain with a newly developed paramagnetic ligand.", SOCIETY FOR NEUROSCIENCE ABSTRACTS., (1999) VOL. 25, NO. 1-2, PP. 1970. MEETING INFO.: 29TH ANNUAL MEETING OF THE SOCIETY FOR NEUROSCIENCE. MIAMI BEACH, FLORIDA, USA OCTOBER 23-28, 1999 SOCIETY FOR NEUROSCIENCE., XP001041587 *

Also Published As

Publication number Publication date
AU2119101A (en) 2001-05-08
WO2001030398A2 (en) 2001-05-03

Similar Documents

Publication Publication Date Title
WO2001030398A3 (en) Ligand chelated paramagnetic mri contrast agents
WO2005017107A3 (en) Specific binding agents to hepatocyte growth factor
WO2005079391A3 (en) Contrast agents for myocardial perfusion imaging
WO2000056774A8 (en) Methods of using bioelastomers
JP2003505519A5 (en)
WO2002087498A3 (en) Diagnostic imaging compositions, their methods of synthesis and use
EP2253333A3 (en) Contrast Agents for Myocardial Perfusion Imaging
WO2007002540A3 (en) Radiolabeled-pegylation of ligands for use as imaging agents
WO2002007846A8 (en) Extended organic cobalt and nickel magnetic complexes
WO2005117848A3 (en) Vascular targets for detecting, imaging and treating neoplasia or neovasculature
WO2001092283A3 (en) Cobalamin compounds useful as cardiovascular agents and as imaging agents
IL177167A0 (en) Method for delivering targeted agents for diagnostic imaging and compositions containing particulate targeted vehicles coupled to a binding ligand
WO2010011367A3 (en) Bimodal ligands with macrocyclic and acyclic binding moieties, complexes and compositions thereof, and methods of using
WO2007006041A8 (en) Imaging and therapeutic method using monocytes
WO2002053533A3 (en) Kappa opioid receptor ligands
WO2003101919A3 (en) Scorpionate-like pendant macrocyclic ligands, complexes and compositions thereof, and methods of using same
MXPA02010801A (en) Cationic diagnostic, imaging and therapeutic agents associated with activated vascular sites.
EP2230254A3 (en) Anti-IGFR1 antibody therapeutic combinations
ATE264862T1 (en) CHLORINE AND BACTERIOCHLORINE-AMINOPHENYLDTPA CONJUGATES AS MR CONTRAST AGENTS AND RADIOPHARMACEUTICS
DE60120047D1 (en) Organic core-shell silver salts and imaging compositions, materials and methods using same
NZ315505A (en) Methods of diagnostic image analysis using metal complexes of nitrogen-containing macrocyclic ligands
DE69915597D1 (en) Composition containing soluble isoflavone and process for its preparation
ATE302175T1 (en) METHOD FOR PRODUCING (18F) RADIOM-LABELED NITROIMIDAZOLE DERIVATIVES FOR DETECTING CELLULAR HYPOXIA
IL114732A0 (en) Macrocyclic chelants their chelates and uses thereof in the diagnostic field
GR3026121T3 (en) Bicycloazamacrocyclophosphonic acid, conjugates, contrast agents and preparation

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP